| Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
| Deepmatter Group Plc |
LSE:DMTR |
London |
Ordinary Share |
GB00B29YYY86 |
ORD 0.01P |
| |
Price Change |
% Change |
Share Price |
Shares Traded |
Last Trade |
| |
0.00 |
0.0% |
2.00 |
504,813 |
11:38:49 |
| Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
|
1.80
|
2.20
|
2.00 |
1.85 |
2.00 |
| Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
|
Chemicals
|
|
-1.99
|
-0.33
|
|
15
|
| Last Trade Time |
Trade Type |
Trade Size |
Trade Price |
Currency |
| 11:38:24 |
O |
24,195 |
2.05 |
GBX |
| Trade Time |
Trade Price |
Trade Size |
Trade Value |
Trade Type |
| 2020-04-08 10:38:26 | 2.05 | 24,195 | 496.00 | O |
| 2020-04-08 10:11:43 | 2.05 | 24,195 | 496.00 | O |
| 2020-04-08 09:29:06 | 2.05 | 20,000 | 410.00 | O |
| 2020-04-08 09:16:36 | 2.05 | 34,146 | 699.99 | O |
| 2020-04-08 09:13:58 | 1.98 | 70,246 | 1,390.87 | O |
| Date | Subject |
|---|
08/4/2020
09:20 | Deepmatter Daily Update: Deepmatter Group Plc is listed in the Chemicals sector of the London Stock Exchange with ticker DMTR. The last closing price for Deepmatter was 2p.
Deepmatter Group Plc has a 4 week average price of 1.55p and a 12 week average price of 1.55p.
The 1 year high share price is 4.30p while the 1 year low share price is currently 1.55p.
There are currently 736,528,946 shares in issue and the average daily traded volume is 244,695 shares. The market capitalisation of Deepmatter Group Plc is £14,730,578.92.
|
11/12/2019
14:14 | noirua: Group PLC DeepMatter collaboration with AstraZeneca
9 December 2019
https://uk.advfn.com/stock-market/london/deepmatter-DMTR/share-news/DeepMatter-Group-PLC-DeepMatter-collaboration-with/81305329
DeepMatter's DigitalGlassware(TM) data collection and structuring technology to be used alongside AstraZeneca's automated compound synthesis platform
Scientists from the two organisations will work together to improve the productivity of synthesising single compounds and compound libraries based on unique, structured data harvested from the DigitalGlassware(TM) technology.
Michael Kossenjans, Associate Director, Discovery Sciences, R&D, AstraZeneca, said:
"Our goal is to transform drug design using innovative digital technologies in combination with automation and AI.
To get potential new medicines to patients faster, we need to reduce the cycle time for lead identification and optimisation and look forward to working with DeepMatter to assess the potential of DigitalGlassware(TM) to help with this."
Mark Warne, CEO of DeepMatter, said:
"We've been impressed with the automated chemistry platforms developed at AstraZeneca sites for autonomous delivery of new lead series.
We see an opportunity to draw together knowledge from the DigitalGlassware(TM) platform to enable machine learning and AI technologies to increase the certainty of producing a high quality and choice of candidate drug molecules.
"We look forward to progressing this exciting collaboration over the coming months as we continue to maximise the potential of the DigitalGlassware(TM) platform."
|
11/12/2019
13:16 | mcrudden: Added more here today, looking at the share price you'd think that nothing had happened this week. Strange
|
Deepmatter share price data is direct from the London Stock Exchange
PLUS1
DeepMatter Platform To Be Adopted By University Of Nottingham